Pharmacoeconomic analysis of switch to faricimab for neovascular age-related macular degeneration in real clinical practice
Global and Regional Health Technology Assessment · 10.07.2026 · 13 (1) · 185-191
DOI: 10.33393/grhta.2026.3800 ↗Kurz gefasst
Fachartikel in der Zeitschrift Global and Regional Health Technology Assessment, online erschienen am 10.07.2026. Verfasst von Jorge Ruiz-Medrano und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Puerta de Hierro-Majadahonda University Hospital, Madrid - Spain. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Neovascular age-related macular degeneration (nAMD) is one of the leading causes of severe visionloss among older adults. This condition impairs patients’ quality of life and imposes a significant economic burdenon the healthcare system. This study aims to determine the difference in direct healthcare cost (DHC) afterswitching the current pharmacological treatment in patients with nAMD, under a treat-and-extend regimen, tofaricimab.
Methods
Treatment interval data obtained after switching to faricimab in 225 eyes with nAMD was used tocalculate total DHC in comparison with the theoretical DHC had if patients remained on their previous treatment(drug and treatment interval). An “optimal responder” was defined as a patient whose interval between intravitalinjections was extended by more than 8 weeks relative to the baseline treatment interval.
Results
The theoretical DHC of treatment for this series of nAMD eyes would have been €2,351,241.90, comparedwith an actual DHC after switching to faricimab of €1,718,015.83, representing a saving of €633,226.06for 225 eyes. The mean theoretical DHC would have been €10,449.96 ± 4,340.18 (from 1,423.75 to 23,695.20),compared with a mean actual total cost of €7,635.62 ± 2,465.07 (from 2,571.88 to 15,431.28). The mean actualDHC was €8,499.74 ± 2,678.42 in the “non-optimal responder” group versus €6,593.59 ± 1,674.91 in the “optimalresponder” group (p < 0.001).
Conclusion
Switching to faricimab in patients with nAMD on a treat-and-extend regimen with a treatment intervalof less than 12 weeks resulted in a significant reduction in total DHC, particularly in the “optimal responder”group.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, Puerta de Hierro-Majadahonda University Hospital, Madrid - Spain.
- Ocular Microsurgery Institute (IMO), Madrid - Spain.
- Department of Ophthalmology, Castilla-La Mancha University, Albacete - Spain.
ORCID-Profile: Jorge Ruiz-Medrano, María Hinojosa-Gonzalez, Carlota Moreno-Alboran, José Ma Ruiz-Moreno
Zitieren
APA
Ruiz-Medrano, J., Puertas, M., Hinojosa-Gonzalez, M., Moreno-Alboran, C., & Ruiz-Moreno, J. M. (2026). Pharmacoeconomic analysis of switch to faricimab for neovascular age-related macular degeneration in real clinical practice. Global and Regional Health Technology Assessment, 13(1), 185-191. https://doi.org/10.33393/grhta.2026.3800
Vancouver
Ruiz-Medrano J, Puertas M, Hinojosa-Gonzalez M, Moreno-Alboran C, Ruiz-Moreno JM. Pharmacoeconomic analysis of switch to faricimab for neovascular age-related macular degeneration in real clinical practice. Global and Regional Health Technology Assessment. 2026;13(1):185-191. doi:10.33393/grhta.2026.3800
BibTeX
@article{RuizMedrano2026,
author = {Ruiz-Medrano, Jorge and Puertas, Mariluz and Hinojosa-Gonzalez, María and Moreno-Alboran, Carlota and Ruiz-Moreno, José Ma},
title = {Pharmacoeconomic analysis of switch to faricimab for neovascular age-related macular degeneration in real clinical practice},
journal = {Global and Regional Health Technology Assessment},
year = {2026},
volume = {13},
number = {1},
pages = {185--191},
doi = {10.33393/grhta.2026.3800}
}
EUVIMED